

Ministry of Health and Long-Term Care

Ontario Public Drug Programs

Drug Submission Status

Complete Streamlined Multiple-Source Submissions for Future Formulary Listing

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Apo-Montelukast	Singulair	montelukast sodium	4mg	chewable tablet	02377608
Apotex Inc.	Apo-Risedronate	Actonel	risedronate sodium hemi-pentahydrate	150mg	coated tablet	02377721
Jamp Pharma Corporation	Jamp-Amlodipine	Novasc	amlodipine besylate	5mg	tablet	02357194
Jamp Pharma Corporation	Jamp-Amlodipine	Novasc	amlodipine besylate	10mg	tablet	02357208
Pharmascience Inc.	Pms-Clopidogrel	Plavix	clopidogrel bisulfate	75mg	FC tablet	02348004
Pharmascience Inc.	Pms-Risperidone ODT	Risperdal M-Tab	risperidone	3mg	OD tablet	02370697
Pharmascience Inc.	Pms-Risperidone ODT	Risperdal M-Tab	risperidone	4mg	OD tablet	02370700
Sandoz Canada Inc.	Sandoz Telmisartan	Micardis	telmisartan	40mg	tablet	02375958

Sandoz Canada Inc.	Sandoz Telmisartan	Micardis	telmisartan	80mg	tablet	02375966
Sandoz Canada Inc.	Sandoz Clopidogrel	Plavix	clopidogrel bisulfate	75mg	FC tablet	02359316
Teva Canada Limited	Teva-Clopidogrel	Plavix	clopidogrel bisulfate	75mg	FC tablet	02293161

Updated: January 13, 2012